184 related articles for article (PubMed ID: 27097807)
41. Pseudopterosin Inhibits Proliferation and 3D Invasion in Triple-Negative Breast Cancer by Agonizing Glucocorticoid Receptor Alpha.
Sperlich J; Teusch N
Molecules; 2018 Aug; 23(8):. PubMed ID: 30103404
[TBL] [Abstract][Full Text] [Related]
42. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
43. The different role of Notch1 and Notch2 in astrocytic gliomas.
Xu P; Zhang A; Jiang R; Qiu M; Kang C; Jia Z; Wang G; Han L; Fan X; Pu P
PLoS One; 2013; 8(1):e53654. PubMed ID: 23349727
[TBL] [Abstract][Full Text] [Related]
44. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
[TBL] [Abstract][Full Text] [Related]
45. Lentiviral vector-mediated doxycycline-inducible USP39 shRNA or cDNA expression in triple-negative breast cancer cells.
Liu S; Liu X; Wang H; Zhou Q; Liang Y; Sui A; Yao R; Zhao B; Sun M
Oncol Rep; 2015 May; 33(5):2477-83. PubMed ID: 25812575
[TBL] [Abstract][Full Text] [Related]
46. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
47. Mimetic sHDL nanoparticles: A novel drug-delivery strategy to target triple-negative breast cancer.
Wang T; Subramanian C; Yu M; White PT; Kuai R; Sanchez J; Moon JJ; Timmermann BN; Schwendeman A; Cohen MS
Surgery; 2019 Dec; 166(6):1168-1175. PubMed ID: 31371177
[TBL] [Abstract][Full Text] [Related]
48. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
49. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
50. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
51. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
52. Withaferin A-induced apoptosis in human breast cancer cells is associated with suppression of inhibitor of apoptosis family protein expression.
Hahm ER; Singh SV
Cancer Lett; 2013 Jun; 334(1):101-8. PubMed ID: 22935676
[TBL] [Abstract][Full Text] [Related]
53. A Comprehensive Review and Perspective on Anticancer Mechanisms of Withaferin A in Breast Cancer.
Hahm ER; Kim SH; Singh KB; Singh K; Singh SV
Cancer Prev Res (Phila); 2020 Sep; 13(9):721-734. PubMed ID: 32727824
[TBL] [Abstract][Full Text] [Related]
54. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
55. DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition.
Bakrania AK; Variya BC; Rathod LV; Patel SS
Eur J Pharm Biopharm; 2018 Jan; 122():37-48. PubMed ID: 29031923
[TBL] [Abstract][Full Text] [Related]
56. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.
O'Neill CF; Urs S; Cinelli C; Lincoln A; Nadeau RJ; León R; Toher J; Mouta-Bellum C; Friesel RE; Liaw L
Am J Pathol; 2007 Sep; 171(3):1023-36. PubMed ID: 17675579
[TBL] [Abstract][Full Text] [Related]
57. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
58. Notch2-induced COX-2 expression enhancing gastric cancer progression.
Tseng YC; Tsai YH; Tseng MJ; Hsu KW; Yang MC; Huang KH; Li AF; Chi CW; Hsieh RH; Ku HH; Yeh TS
Mol Carcinog; 2012 Dec; 51(12):939-51. PubMed ID: 21976141
[TBL] [Abstract][Full Text] [Related]
59. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
